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Abstract The human immunode¢ciency virus (HIV-1) Nef pro-
tein is now regarded as a regulatory protein responsible not only
for establishment of infection and increased pathogenesis but
also for enhancement of viral replication. However, the mecha-
nism of Nef-induced activation of viral replication remains to be
clearly understood. Using transient transfection assay, co-immu-
noprecipitation and pull-down analysis, we demonstrate in this
report that the HIV-1 Nef protein physically interacts with Tat,
the principal transactivating protein of HIV-1. Our observations
with single cycle replication experiments further indicate that
this interaction results not only in enhancement of Tat-induced
HIV-1 long terminal repeat-mediated gene expression but also
in virus production.
& 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The Nef protein of the human immunode¢ciency virus
(HIV) is a 25^30 kDa cytoplasmic phosphoprotein expressed
abundantly at all stages of HIV-1 infection and is known to
be a crucial element in determining viral pathogenicity [1^3].
The contribution of Nef protein to the induction of acquired
immunode¢ciency syndrome (AIDS) can be explained by at
least three properties that have been ascribed to Nef, namely:
(i) down-modulation of cell surface proteins such as CD4 and
MHC I, (ii) enhancement of viral infectivity and (iii) induction
of T cell activation pathways [4]. The identi¢cation of cellular
proteins interacting with Nef both in vitro and in vivo has
strengthened the concept that Nef acts as a modulator of
intracellular activation pathways [4,5].
Upon infection of susceptible cells and integration into the
host genome, transcription of the HIV-1 genes is dependent
on the concerted action of the cellular transcription machinery
and of the viral transactivating protein, Tat [6]. Tat is an 86^
104 residue protein essential for HIV-1 replication as it acts as
a potent activator of viral gene expression. Tat binds to a
bulge sequence within the transactivating region, a highly
structured RNA element located at the 5P ends of all viral
transcripts, and acts by a dual mechanism. It increases both
the rate of initiation and transcriptional elongation by aug-
menting the activity of RNA polymerase II [7]. HIV-1 Tat
stimulates the growth of some cell types and induces apoptosis
in others in addition to inducing the expression of various
cytokines [8,9].
The role of Nef in the viral replication process has been a
subject of debate over the years. In early studies, Nef was
reported to have a negative e¡ect on viral replication in
T cell lines [10] but it was later shown to have a positive e¡ect
in peripheral blood mononuclear cells [11]. Ahmad and Ven-
katesan [12] reported a transcriptional suppressor activity for
Nef, however, two other groups could not corroborate this
negative e¡ect [13,14] and at least one group has shown tran-
scriptional enhancing activity for Nef in macrophages [15].
Some recent reports have shown clear evidence of Nef being
an enhancer of viral replication in many cell types [16^18],
though the molecular mechanism of this e¡ect has not been
elucidated. Studies to date have tried to characterize long
terminal repeat (LTR)-mediated gene expression with respect
to either Tat or Nef individually but not in the presence of
both, which we believe is very important for HIV-1 LTR-
mediated gene expression as both are early proteins. The cur-
rent study was therefore undertaken to understand the role of
Nef in viral gene expression, in the presence of Tat, and also
to determine if these two proteins interact and thereby in£u-
ence HIV replication and pathogenesis.
2. Materials and methods
2.1. Expression vectors, cell lines and antibodies
Tat expression vector was constructed by cloning the complete tat
open reading frame from pCV1, a HXB3 tat and rev coding vector
[19], in pCDNA 3.1 (Invitrogen, USA). The Nef expression vector was
constructed by polymerase chain reaction ampli¢cation of the Nef
fragment from the HXB3 proviral DNA [20] and cloning into
pCDNA 3.1. Nl4.3 Nef cloned in pCDNA was a kind gift of Dr.
M. Federico. A frameshift mutant of Nef at amino acid 33 due to
insertion of an XhoI site was cloned in pCDNA3.1 from the molecular
clone [21]. pCDNA-CAT reporter vector containing the chloramphen-
icol acetyltransferase (CAT) gene under the cytomegalovirus (CMV)
promoter was used as a control. pEGFPN-Tat and pDsRed-Nef were
constructed by sub-cloning the tat and nef gene fragments as N-ter-
minal fusion to green £uorescent protein (GFP) and red £uorescent
protein (RFP) in pEGFPN1 and pDsRed1N1 respectively (Clontech,
USA). All the constructs were con¢rmed by nucleotide sequencing
and protein expression. Jurkat and CEM cells (CD4þ human T cell
lines), U87MG cells (human astroglial cell line) and 293T cells (hu-
man embryonic kidney) were obtained from the NCCS cell repository,
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India. H9/HTLV-IIIB [22] and Jurkat 1G5 cells [23] were obtained
from the NIH AIDS repository. Polyclonal antibody to Tat was ob-
tained from the NIH AIDS repository [7] and Autogen Bioclear, UK.
Monoclonal Tat antibodies were a kind gift of Dr. V. Ovod (Finland).
Polyclonal Nef antibody was obtained from the NIH AIDS repository
[24].
2.2. Transfection, viral infection and quantitation
Transient transfections in Jurkat and U87MG cells with Tat and/or
Nef expression vectors along with the reporter vector pU3R3 [25]
were performed using Lipofectamine or Lipofectamine 2000 reagent
respectively (Gibco BRL, USA). Transfection e⁄ciency was normal-
ized by co-transfecting CMV L-gal plasmid (Clontech, USA), and
measuring the L-gal activity prior to CAT estimation as previously
described [26].
293T cells were transfected with Tat and Nef expression vectors
using calcium phosphate precipitation and harvested 48 h post trans-
fection followed by immunoprecipitation and immunoblotting [27].
Single cycle replication studies were done in 293T cells, which were
transfected using Lipofectamine 2000 with the molecular clones of
wild type NL4.3 or a Nef-deleted clone of NL4.3 [28]. The transfec-
tion e⁄ciency was monitored by co-transfection of GFP-expressing
vector pEGFPN1. The cells were harvested 36 h post transfection for
the CAT assay. The culture supernatants collected at the same time
were used to determine virus production by p24gag antigen capture
enzyme-linked immunosorbent assay (ELISA; NEN, USA). CEM
cells were infected with HIV-1 NL4.3 virus using 100 ng of p24 units
per 2U106 cells as described previously [29].
2.3. Protein analysis
The Tat and Nef proteins were generated by coupled in vitro tran-
scription and translation as per the manufacturer’s instructions
(Promega, USA). The [35S]methionine-labeled Tat and Nef proteins
were incubated together in binding bu¡er (20 mM HEPES pH 7.4,
1 mM dithiothreitol, 2 mM MgCl2, 100 Wg/ml bovine serum albumin)
at 4‡C and immunoprecipitated using polyclonal antibodies against
either Tat or Nef [7,24]. Protein A-Sepharose (Amersham, USA)-im-
mobilized complexes were washed extensively and resuspended in
Laemmli’s sample bu¡er followed by resolution on a 15% sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE).
The gel was prepared for £uorography as described elsewhere [30]
and then exposed to X-ray ¢lm.
pGEX-Tat-transformed BL21DE3 Escherichia coli cells [31] were
induced with isopropyl-L-D-thiogalactose to produce GST-Tat pro-
tein, which was then puri¢ed using glutathione-Sepharose beads
(Amersham, USA). CEM cells (5U106) were harvested 9 days post
infection and lysed in radioimmunoprecipitation assay (RIPA) bu¡er
(20 mM Tris^HCl pH 7.2, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS
and 1% sodium deoxycholate) with protease inhibitor cocktail (Roche,
Germany). The clari¢ed supernatant (10 000Ug) was incubated with
either glutathione S-transferase (GST) or GST-Tat immobilized on
glutathione-Sepharose beads at 4‡C and subjected to ¢ve washes
with RIPA bu¡er. The complexes were resuspended in Laemmli’s
sample bu¡er, boiled, and resolved on 15% SDS^PAGE.
H9-IIIB cells were activated with phorbol 12-myristate 13-ace-
tate(PMA) for 72 h prior to immunoprecipitation. Cells were lysed
in Dignam bu¡er (20 mM HEPES pH 7.4, 25% glycerol, 0.42 M
NaCl, 1.5 M MgCl2, 0.2M EDTA, 0.5 mM phenylmethylsulfonyl
£uoride and 0.5 mM dithiothreitol) on ice for 30 min. Clari¢ed lysates
were incubated with polyclonal antibody to the Tat protein (Auto-
gen). The antigen^antibody conjugate was pulled down by binding
with a mixture of protein A and protein G agarose beads followed
by resolution on 15% SDS^PAGE. The blots were probed with anti-
body to the Nef protein [24] and developed using the enhanced chemi-
luminescence (ECL Plus) system (Amersham, USA).
2.4. Confocal microscopy
293T cells grown on coverslips were transfected using either
pEGFPN1-Tat and/or pDsRed1N1-Nef by the calcium phosphate
method. Cells were harvested 24 h post transfection and ¢xed in
3.7% paraformaldehyde prior to viewing with an Ultraview confocal
imaging system (Perkin-Elmer) using an Olympus X70 microscope.
Fig. 1. Enhancement of Tat-mediated transactivation by the Nef protein from the HIV-1 LTR in Jurkat, U87MG and Jurkat 1G5 cells. A: Jur-
kat T cells were transfected with the vectors pU3R3 (1 Wg), pCDNA-Tat (0.3 Wg) and pCDNA-Nef (1 Wg) or pCDNA-Nef (M) mutant (1 Wg)
as indicated below each bar and as described in detail in the text. CAT activity was assayed 36 h post transfection, after normalization of
L-gal activity. B: Jurkat T cells were transfected with the vectors pCDNA-CAT (1 Wg), pCDNA-Tat (0.3 Wg) and pCDNA-Nef (1 Wg) as indi-
cated. CAT activity was assayed 36 h post transfection, after normalization of L-gal activity. C: U87MG cells were transfected with the vectors
pU3R3 (1 Wg), pCDNA-Tat (0.1 Wg) and pCDNA-Nef (1Wg) as indicated. CAT activity was assayed 36 h post transfection after normalization
of L-gal activity. D: Jurkat 1G5 cells were transfected with vectors pCDNA-Tat (0.5 Wg) or pCDNA-Nef (2 Wg) or both as indicated. Lucifer-
ase assays of the lysates were performed after 24 h following L-gal normalization as described in the text. The histograms show the means of
three independent experiments with error bars representing S.E.M.
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3. Results
3.1. Nef enhances Tat-mediated transactivation from
the HIV-1 LTR
There have been con£icting reports about the role of the
Nef protein in transactivation of HIV-1 LTR-driven gene ex-
pression. To reconcile the divergent observations, we revisited
the ability of Nef to transactivate the HIV-1 LTR in the
presence of Tat. Co-transfection of Jurkat cells with equal
amounts of Tat and Nef expression vectors showed a de¢nite
increase in Tat-mediated transactivation as compared to Tat
or Nef alone (data not shown). In an attempt to delineate the
Nef-mediated transactivation in the presence of Tat, we re-
duced Tat to sub-optimal levels in later transfections. As
shown in Fig. 1A, at least a two-fold increase in CAT activity
was repeatedly observed in the presence of Nef and Tat, as
compared to Jurkat cells transfected with Tat alone. Nef from
di¡erent HIV-1 isolates, i.e. SF2, NL4.3, NA7, and subtype C
93IN904 on co-transfection with Tat showed a similar en-
hancement of transactivation (data not shown). However,
this Nef-mediated enhancement of transactivation was not
observed in the presence of mutated Nef (Fig. 1A). A control
experiment with the CMV promoter did not show any e¡ect
of Nef, although Tat seemed to enhance the gene expression
to some extent (Fig. 1B) as reported in the literature [32]. In
order to test whether the same e¡ect is observed in cells of
non-lymphoid origin, the microglial cell line U87MG was
used to study the role of Nef in Tat-induced transactivation.
Similar results were observed in U87MG cells where again a
consistent two-fold increase in transactivation was seen upon
co-transfection of Nef with Tat (Fig. 1C) as compared to Tat
alone. To substantiate this e¡ect, we further studied this phe-
nomenon in 1G5 cells, which contain a stably integrated lu-
ciferase reporter gene under the control of the HIV-1 LTR
promoter. Our data with co-transfection of Nef and Tat plas-
mids in 1G5 cells show a similar two-fold increase in lucifer-
ase activity as compared to Tat alone (Fig. 1D). As the two
cell lines, Jurkat and U87MG, di¡er greatly in their origin,
there is a possibility that this observed transactivation is im-
portant for gene expression from the HIV-1 LTR. This led us
to explore the possibility of an interaction between the two
proteins, Tat and Nef.
3.2. The Nef protein interacts with HIV-1 Tat in vitro and
in vivo
Coupled in vitro transcription and translation provides a
powerful and easy tool to study proteins in a pure state.
Therefore, [35S]Met-labeled Tat and Nef proteins were incu-
bated together and immunoprecipitation carried out using ei-
ther anti-Nef or anti-Tat antibodies (Fig. 2B). To rule out the
possibility of a non-speci¢c interaction between two proteins,
labeled CAT protein was used as a control. Fig. 2A clearly
shows the absence of any non-speci¢c interaction of Tat or
Nef with CAT protein (lanes 2^3) and also demonstrates that
the Tat and Nef antibodies do not cross-react with each other
(lanes 4^5). The results obtained from Tat^Nef interaction
clearly showed that Tat co-immunoprecipitated with the Nef
protein and vice versa (Fig. 2B, lanes 3 and 5). Thus the data
indicate that the Nef protein directly interacts with Tat in
vitro. The slower-migrating band of Nef with a molecular
mass of V27 kDa seems to be the full-length Nef protein
whereas the faster-migrating V25 kDa band corresponds to
the Nef protein synthesized as a result of translation initiation
from an internal methionine start site [1]. Our data further
indicate that the Nef protein which associates with the Tat
protein could be the full-length Nef species, since the lower
molecular mass band was almost absent when immunoprecip-
itation was done with anti-Tat antibody (Fig. 2B, lane 3).
In contrast, when anti-Nef antibody was used to immuno-
precipitate, both the Nef bands were pulled down along
with Tat, as the antibody recognizes both forms of Nef
(Fig. 2B, lane 5).
Fig. 2. Interaction of Tat and Nef proteins in vitro and in vivo.
A: [35S]Met-labeled Tat and Nef proteins were synthesized using in
vitro coupled transcription and translation as described in the text.
The two proteins were incubated with CAT protein, followed by im-
munoprecipitation with Tat or Nef antisera as a control experiment.
The antibodies were also tested for cross-reactivity with each other.
The proteins were resolved on 15% SDS^PAGE and autoradio-
graphed as detailed in the text. B: The labeled Tat and Nef proteins
were incubated with each other followed by immunoprecipitation
with Tat or Nef antisera as shown. The immunoprecipitated com-
plexes were analyzed on SDS^PAGE as described in A. C: 293T
cells were transfected with Tat expression vector or both Tat and
Nef as described in the text. After 36 h, the cells were lysed, immu-
noprecipitated with anti-Nef antibody followed by immunoblotting
with anti-Tat antibody as indicated.
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The binding of Tat and Nef proteins in vitro could not be
ruled out due to localized concentrations of the two proteins.
Hence transfections in 293T cells were performed with either
expression plasmid or a combination of both. Fig. 2C shows
that the Tat protein co-immunoprecipitates with the Nef pro-
tein. This is signi¢cant as both these proteins are known to
interact with a number of cellular factors involved in tran-
scription and cellular signaling and Nef has been hypothesized
to act as an adapter molecule.
3.3. GST-Tat pull-down analysis and co-immunoprecipitation
using HIV-1-infected cells
The Tat and Nef proteins are reported to be early HIV
proteins synthesized in an infected cell and thus provide an
established system to show Tat and Nef association. We uti-
lized a precipitation assay wherein cell lysates of HIV-1-in-
fected CEM cells were incubated with GST-Tat beads (Fig.
3A) for pull-down analysis. The results (Fig. 3B, lane 1) depict
that the Nef protein is speci¢cally pulled down from infected
CEM cell lysates by GST-Tat beads. As expected, the empty
GST-agarose beads did not precipitate Nef (Fig. 3B, lane 2).
Lanes 3 and 4 show the presence of the Nef protein in the
infected cell lysate and not in the uninfected cells. These data
provide clear evidence of an interaction between the Tat and
Nef proteins in the context of HIV infection.
Phorbol esters such as PMA stimulate the transcription and
translation machinery of T cells and thus also enhance tran-
scription from the HIV-1 LTR [17]. H9-IIIB, a chronically
infected T cell line, was stimulated with PMA for 72 h prior
to harvesting. Lysates were subjected to immunoprecipitation
with antibody to Tat, followed by immunoblotting with poly-
clonal antibody against the Nef protein. Fig. 3C shows the
presence of the Nef protein in only the chronically infected
cell lysates and not in H9 cell lysate. Thus the viral proteins
Tat and Nef do exist as a complex even in infected cells,
thereby con¢rming our in vitro data of Tat and Nef physically
interacting with each other.
3.4. Co-localization of Nef and Tat proteins in transfected cells
Nef has been shown to activate T cells or inhibit their
activation depending upon its subcellular location [33] and it
would seem pertinent to analyze the localization of Nef in
relation to Tat. Tat, although regarded primarily as a nuclear
protein, has been reported to interact with an array of cellular
proteins and subvert signaling pathways. Nef has been shown
Fig. 3. Interaction of Tat and Nef: pull-down analysis using GST-
Tat and co-immunoprecipitation in infected cells. A: Coomassie-
stained SDS^polyacrylamide gel showing relative mobility of GST
and GST-Tat proteins. Protein markers are indicated on the left (in
kDa). B: GST-Tat (lane 1) or GST (lane 2) beads were incubated
with infected CEM cell lysate followed by SDS^PAGE and immu-
noblotting with Nef antiserum as mentioned in the text. The NL4.3-
infected (lane 3) and uninfected CEM (lane 4) cell lysates were run
in parallel and probed with Nef antiserum as controls. The arrow
indicates the position of the Nef protein. C: PMA-activated H9-
IIIB cells were lysed and subjected to immunoprecipitation using
polyclonal antibody to the Tat protein, followed by immunoblotting
with antibody to Nef. Lanes 1 and 2 depict the control H9 cell ly-
sate and the infected cell lysate respectively.
Fig. 4. Localization of Tat and Nef in co-transfected 293T cells.
A: 293T cells were grown on coverslips and transfected with
pEGFPN1-Tat (2 Wg) and pDsRed1N1-Nef (2 Wg). The transfected
cells were visualized after 24 h by confocal microscopy as detailed
in the text. B: Graph depicts cells positive for expression of both
Tat and Nef proteins localized in the nucleus or having a dispersed
localization.
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as a predominantly cytoplasmic protein in transfected cells ;
however, it has also been shown to be present in the nucleus
of HIV-1-infected and transfected cells [34^36]. Expression of
GFP-Tat and RFP-Nef was utilized to study the cellular local-
ization of these proteins in context with each other. Expres-
sion of these fusion proteins independently of each other
showed a very dispersed localization within the cells. How-
ever, there was a marked di¡erence in the localization pattern
when these fusion proteins were co-expressed in 293T cells as
shown in Fig. 4A. At least 70% of cells expressing both pro-
teins showed a marked nuclear localization and the remaining
30% of cells showed a dispersed localization pattern (Fig. 4B).
This observation is of signi¢cance as our earlier data clearly
show that Nef physically interacts with Tat, which is involved
in transcriptional transactivation in the nucleus. Nuclear co-
localization of these two proteins in a majority of cells could
be due to the interaction and their role in enhancement in
gene expression as indicated by our transactivation experi-
ments.
3.5. Role of Nef in LTR-mediated gene expression and virus
production in vivo
To determine the role of this observed interaction between
Tat and Nef in vivo, we designed an assay to measure the
levels of transactivation from the HIV-1 LTR and virus pro-
duction in a single cycle replication experiment with 293T cells
which are CD43 and are thus refractory to infection. Molec-
ular clones of HIV-1 were used to determine the levels of
transactivation using the CAT assay and p24 levels were
used to determine virus production after normalizing the
transfection using GFP expression. The Nef-deleted clone
shows lower levels of transactivation as compared to the in-
tact NL4.3 clone (Fig. 5A), which are restored to wild-type
levels by co-transfecting cells with the Nef expression con-
struct, thereby indicating the importance of Nef in viral
gene expression. The p24 values also show a similar pattern
with an increase in virus production in cells co-transfected
with the Nef3 NL4.3 and pCDNA3.1-Nef, as compared to
the Nef-deleted viral clone (Fig. 5B). These data clearly indi-
cate that expression of the Nef protein even in trans can con-
fer an increased level of gene expression as well as virus pro-
duction. Similar results were also obtained using pR7-GFP
[37], a Nef-deleted molecular clone, which indicates that it is
not an allele-speci¢c phenomenon and is an integral part of
the viral infection strategy (data not shown). This experiment
also points towards a direct correlation between activation of
viral gene expression and viral replication.
4. Discussion
Although Nef has been shown to enhance the infectivity
and replication of HIV-1, the molecular basis of this enhance-
ment is not clearly elucidated. Speci¢cally, the role of Nef in
HIV-1 gene expression as measured by its e¡ect on the HIV-1
promoter LTR has been a subject of controversy. Nef was
earlier characterized with a capacity to silence the LTR, fol-
lowed by neutral and later with positive e¡ects on LTR-based
transcription [10^15]. Therefore the e¡ects of Nef on the LTR
are diverse, which could be due to di¡erences in the cell lines
used, the strains of Nef used and the cellular localization of
the Nef protein. Some recent studies have clearly shown that
Nef induces Tat-mediated HIV-1 LTR-driven gene expression
[17,33,38] which the authors attribute to activation of T cells
and activation of some transcription factors. The data pre-
sented in the current study re£ect the importance of Nef pro-
tein in the viral transcription along with Tat protein. Our
observations of enhanced transactivation of Tat-induced
HIV-1 LTR-mediated gene expression in the presence of
Nef corroborate the recent reports mentioned above
[17,33,38]. Our experiments for the ¢rst time show that the
two regulatory proteins, Tat and Nef, interact amongst them-
selves and our data also indicate that this enhancement of
transactivation is probably mediated by a functional interac-
tion between these two important regulatory proteins. The co-
localization of Nef and Tat in the nucleus as visualized using
confocal microscopy points toward a possible role of Nef in
the Tat transcription complex and con¢rms earlier observa-
tions of Nef localization in the nucleus of transfected and
infected cells [34^36]. The present study also suggests that
interaction between these two proteins exists in HIV-1-in-
fected cells which leads us to postulate that there lies an im-
portant regulatory platform engineered by these two proteins,
which determines optimal viral infection.
Finally, our data show a direct correlation between LTR-
mediated gene expression and virus production and thus pro-
vides a molecular basis for the Nef-induced enhancement of
viral replication as shown directly by a number of studies in a
Fig. 5. Role of Nef on transactivation and virus production in 293T
cells. A: 293T cells were transfected with pU3R3 reporter vector
along with viral clones (100 ng) and Nef expression vector (1 Wg) as
indicated. CAT activity was determined 36 h post transfection as
described in the text. B: Determination of virus production in cul-
ture supernatants of transfected 293T cells described in A, using
HIV-1 p24 antigen capture ELISA. The histograms represent means
of three independent experiments with error bars indicative of
S.E.M.
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variety of cell types [39,40]. Our single cycle replication data
match perfectly time course replication data observed in Jur-
kat cells using di¡erent Nef mutants [18]. Finally, the data
presented here clearly indicate that Nef may enhance viral
replication by binding to Tat in addition to the activation
of T cell function reported earlier. The interaction between
these two proteins lays open the entire cell machinery whether
it be activation, signal transduction, transcription or e¡ector
function to manipulation, thereby leading the cell to which-
ever fate the infection status deems ¢t.
Acknowledgements: The following reagents were obtained through the
AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: V HXB3, H9/HTLV IIIB, pGM93, GST-Tat 1 86R,
HIV-1 Nef and Tat antiserum, pR7-GFP, and Jurkat 1G5 cells. The
pNL4.3, pNEF3 NL4.3, pEFBOS-SF2 Nef vectors were provided by
K. Saksela. We thank Dr. K. Saksela for providing his laboratory
infrastructure at the Institute of Medical Technology, University of
Tampere, Finland, for some experiments and for constructive
criticism. We are indebted to Dr. G.C. Mishra, Director, NCCS for
constant encouragement and support. A.M.J. is supported by a fel-
lowship from the University Grants Commission, India and J.S.L. by
a fellowship from the Council of Scienti¢c and Industrial Research,
India.
References
[1] Guy, B., Kieny, M.P., Riviere, Y., LePeuch, C., Dott, K., Gi-
rard, M., Montagnier, L. and Lecocq, J-P. (1987) Nature 330,
266^269.
[2] Klotman, M.E., Kim, S., Buchbinder, A., DeRossi, A., Balti-
more, D. and Wong-Staal, F. (1991) Proc. Natl. Acad. Sci.
USA 88, 5011^5015.
[3] Kestler, H.W., Ringler, D.J., Mori, K., Panicali, D.L., Schgal,
D.K., Daniel, M.D. and Desrosiers, R.C. (1991) Cell 65, 651^
662.
[4] Renkema, H.G. and Saksela, K. (2000) Front. Biosci. 5, 268^283.
[5] Oldridge, J. and Marsh, M. (1998) Trends Cell Biol. 8, 302^305.
[6] Cullen, B. (1993) Cell 73, 417^420.
[7] Hauber, J., Perkin, A., Heimer, E. and Cullen, B. (1987) Proc.
Natl. Acad. Sci. USA 8, 6364^6368.
[8] Sastry, K.H., Reddy, H.R., Pandita, R., Totpal, K. and Aggar-
wal, B.B. (1990) J. Biol. Chem. 265, 20091^20093.
[9] Westendorp, M.O., Frank, R., Oschsenbauer, C., Stricker, K.,
Dhein, J., Walczak, H., Debatin, K.M. and Krammer, P.H.
(1995) Nature 375, 497^500.
[10] Neiderman, T.M.J., Thielan, B.J. and Ratner, L. (1989) Proc.
Natl. Acad. Sci. USA 86, 1128^1132.
[11] Miller, M.D., Warmerdam, M.T., Gasten, I., Greene, W.C. and
Feinberg, M.B. (1994) J. Exp. Med. 179, 101^113.
[12] Ahmad, N. and Venkatesan, S. (1988) Science 241, 1481^1485.
[13] Hammes, R.S., Dixon, P.E., Malim, M.M., Cullen, R.B. and
Greene, W.C. (1989) Proc. Natl. Acad. Sci. USA 86, 9549^9553.
[14] Kim, S., Ikeuchi, K., Byrn, R., Groopman, J. and Baltimore, D.
(1989) Proc. Natl. Acad. Sci. USA 86, 9544^9548.
[15] Murphy, K.M., Sweet, M.J., Ross, I.L. and Hume, D.A. (1993)
J. Virol. 67, 6956^6964.
[16] Glushakova, S., Grivel, J.C., Suryanarayana, K., Meylan, P.,
Lifson, J.D., Desrosiers, R. and Margolis, L. (1999) J. Virol.
73, 3968^3974.
[17] Simmons, A., Aluvihare, V. and McMichael, A. (2001) Immunity
14, 763^777.
[18] Papkalla, A., Mu«nch, J., Otto, C. and Kirchho¡, F. (2002)
J. Virol. 76, 8455^8459.
[19] Arya, K.S., Guo, C., Josephs, S.F. and Wong-Staal, F. (1985)
Science 229, 69^73.
[20] Shaw, G.M., Hahn, B.H., Arya, S.K., Groopman, J.E., Gallo,
R.C. and Wong-Staal, F. (1984) Science 226, 1165^1170.
[21] Geleziunas, R., Xu, W., Takeda, K., Ichijo, H. and Greene, W.C.
(2001) Nature 410, 834^838.
[22] Popovic, M., Sarangadharan, M.G., Read, E. and Gallo, R.C.
(1984) Science 224, 497^500.
[23] Aguilar-Cordova, E., Chinen, J., Donehower, L., Lewis, D.E.
and Belmont, J.W. (1994) AIDS Res. Hum. Retroviruses 10,
295^301.
[24] Shugars, D.C., Smith, M.S., Glueck, D.H., Nantermet, P.V.,
Seillier-Moiseiwitsch, F. and Swanstorm, R. (1993) J. Virol. 67,
4639^4650.
[25] Rosen, C.A., Sodroski, J.G., Campbell, K. and Haseltine, W.A.
(1986) J. Virol. 57, 379^384.
[26] Mitra, D., Sikder, S.K. and Laurence, J. (1995) Virology 214,
512^521.
[27] Manninen, A., Hiipakka, M., Vihinen, M., Lu, W., Mayer, J.B.
and Saksela, K. (1998) Virology 250, 273^282.
[28] Connor, R.I., Chen, B.K., Choe, S. and Landau, N.R. (1995)
Virology 206, 935^944.
[29] Liu, D., Donegan, J., Nuovo, G., Mitra, D. and Laurence, J.
(1997) J. Virol. 71, 4079^4085.
[30] Bonner, W.M. (1983) Methods Enzymol. 96, 215^222.
[31] Rhim, H., Echetebu, C.O., Hermann, C.H. and Rice, A.P. (1994)
J. AIDS 7, 1116^1121.
[32] Kim, Y.S. and Riser, R. (1993) J. Virol. 67, 239^248.
[33] Baur, S.A., Sawai, T.E., Dazin, P., Fantl, J.W., Cheng-Mayer, C.
and Peterlin, M.B. (1994) Immunity 1, 373^384.
[34] Ovod, V., Lagerstedt, A., Ranki, A., Gombert, O.F., Spohn, R.,
Tahtinen, M., Jung, G. and Krohn, J.K. (1992) AIDS 6, 25^34.
[35] Kienzle, N., Bachmann, M., Muller, E.W. and Muller-Lantzsch,
N. (1992) Arch. Virol. 124, 123^132.
[36] Murti, K.G., Brown, P.S., Ratner, L. and Garcia, J.V. (1993)
Proc. Natl. Acad. Sci. USA 90, 11895^11899.
[37] Page, K., Leigler, T. and Feinberg, M.A. (1997) AIDS Res.
Hum. Retroviruses 13, 1077^1081.
[38] Manninen, A., Renkema, H.R. and Saksela, K. (2000) J. Biol.
Chem. 275, 16513^16517.
[39] Varin, A., Manna, K.S., Quivy, V., Decrion, A-Z., Lint, V.C.,
Herbein, G. and Aggarwal, B.B. (2003) J. Biol. Chem. 24, 2219^
2227.
[40] Lundquist, C.A., Tobiume, M., Zhou, J., Unutmaz, D. and
Aiken, C. (2002) J. Virol. 76, 4625^4633.
FEBS 27462 15-7-03 Cyaan Magenta Geel Zwart
A.M. Joseph et al./FEBS Letters 548 (2003) 37^4242
